HM03 (HM-03) is a novel, potent and selective HSPA5 (also known as Heat shock 70kDa protein 5, Bip, Grp78) inhibitor with anticancer activity.
Physicochemical Properties
| Molecular Formula | C26H27CLN4O2 |
| Molecular Weight | 471.2098 |
| Exact Mass | 498.159 |
| Elemental Analysis | C, 67.45; H, 5.88; Cl, 7.66; N, 12.10; O, 6.91 |
| CAS # | 500565-15-1 |
| Related CAS # | HM03 trihydrochloride;1082532-95-3 |
| PubChem CID | 421105 |
| Appearance | Pink to red solid powder |
| LogP | 5.346 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 33 |
| Complexity | 633 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CN1CCN(CC1)CC2=C(C=CC(=C2)NC3=C4C=C(C=CC4=NC5=C3C=CC(=C5)Cl)OC)O |
| InChi Key | SUSDGTMJKOGWSZ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C26H27ClN4O2/c1-30-9-11-31(12-10-30)16-17-13-19(4-8-25(17)32)28-26-21-6-3-18(27)14-24(21)29-23-7-5-20(33-2)15-22(23)26/h3-8,13-15,32H,9-12,16H2,1-2H3,(H,28,29) |
| Chemical Name | 4-[(6-chloro-2-methoxyacridin-9-yl)amino]-2-[(4-methylpiperazin-1-yl)methyl]phenol |
| Synonyms | HM03; HM-03; HM 03; F06; NSC130813; NSC-130813; NSC 130813 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | HSPA5 |
| ln Vitro | At a binding concentration of 25 μM, HM03 (0.1-50 μM; 72 hours) shows over 50% inhibition in HCT116 cells [1]. When combined with HSPA5 and HSPA9, HM03 forms more sensitive cells than other HSP70 proteins. |
| Cell Assay |
Cell Viability Assay[1] Cell Types: HCT116 cells Tested Concentrations: 0.1, 1, 10, 25, 50 μM Incubation Time [1]. Incubation Duration: 72 hrs (hours) Experimental Results: Demonstrated significant inhibitory effect (18% survival rate at 25 µM). |
| References |
[1]. Structure-based design of HSPA5 inhibitors: from peptide to small molecule inhibitors. Bioorg Med Chem Lett. 2013;23(10):3044‐3050. |
Solubility Data
| Solubility (In Vitro) | DMSO: ~125 mg/mL (~270.0 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (13.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1222 mL | 10.6110 mL | 21.2220 mL | |
| 5 mM | 0.4244 mL | 2.1222 mL | 4.2444 mL | |
| 10 mM | 0.2122 mL | 1.0611 mL | 2.1222 mL |